Tech Company Financing Transactions

Numab Therapeutics Funding Round

Numab Therapeutics, based in Horgen, secured $55 million in investment from Cormorant Asset Management, Forbion Capital Partners and HBM Healthcare Investments.

Transaction Overview

Company Name
Numab Therapeutics
Announced On
1/10/2025
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series C
Investors

Cormorant Asset Management (Lead Investor) (Bihua Chen)

Forbion Capital Partners (Lead Investor)

HBM Healthcare Investments (Lead Investor)

Novo Holdings (Lead Investor)

BlackRock

BVF Partners

Octagon Capital

RTW Investments

Proceeds Purpose
Proceeds from the financing will help accelerate and further advance Numab's pipeline of clinical and pre-clinical best-in-class and first-in-class multi-specific antibodies in inflammation and oncology.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Bachtobelstrasse 5
Horgen, CH-8810
Switzerland
Phone
Undisclosed
Website
www.numab.com
Email Address
[email protected]
Overview
We are developing multi-specific antibody-based immunotherapies for inflammation and cancer. Reproducible plug-and-play therapeutic design process using proprietary platforms ?-Cap� and MATCH� puts Numab in a unique position to overcome historical drug discovery barriers and build a pipeline of new and important medicines aimed to maximize patient benefits. Diverse research pipeline spans multiple therapeutic areas and creates the opportunity for the next generation of first-in-class and best-in-class medicines.
Profile
Numab Therapeutics LinkedIn Company Profile
Social Media
Numab Therapeutics Company Twitter Account
Company News
Numab Therapeutics News
Facebook
Numab Therapeutics on Facebook
YouTube
Numab Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chairman
Carlo Incerti
  Carlo Incerti LinkedIn Profile  Carlo Incerti Twitter Account  Carlo Incerti News  Carlo Incerti on Facebook
Chief Executive Officer
David Urech
  David Urech LinkedIn Profile  David Urech Twitter Account  David Urech News  David Urech on Facebook
Chief Financial Officer
Roland Helfenstein
  Roland Helfenstein LinkedIn Profile  Roland Helfenstein Twitter Account  Roland Helfenstein News  Roland Helfenstein on Facebook
Chief Operating Officer
Sebastian Meyer
  Sebastian Meyer LinkedIn Profile  Sebastian Meyer Twitter Account  Sebastian Meyer News  Sebastian Meyer on Facebook
Vice President
Tea Gunde
  Tea Gunde LinkedIn Profile  Tea Gunde Twitter Account  Tea Gunde News  Tea Gunde on Facebook
Vice President
Martin Stern
  Martin Stern LinkedIn Profile  Martin Stern Twitter Account  Martin Stern News  Martin Stern on Facebook
Vice President
Elmar vom Baur
  Elmar vom Baur LinkedIn Profile  Elmar vom Baur Twitter Account  Elmar vom Baur News  Elmar vom Baur on Facebook
Vice President
Stefan Warmuth
  Stefan Warmuth LinkedIn Profile  Stefan Warmuth Twitter Account  Stefan Warmuth News  Stefan Warmuth on Facebook
VP - Bus. Development
Mireia Gómez-Angelats
  Mireia Gómez-Angelats LinkedIn Profile  Mireia Gómez-Angelats Twitter Account  Mireia Gómez-Angelats News  Mireia Gómez-Angelats on Facebook
VP - General Counsel
James Singleton
  James Singleton LinkedIn Profile  James Singleton Twitter Account  James Singleton News  James Singleton on Facebook
VP - R & D
Daniel Snell
  Daniel Snell LinkedIn Profile  Daniel Snell Twitter Account  Daniel Snell News  Daniel Snell on Facebook

 

 

Browse more venture capital transactions:

Prev: 1/10/2025: METIS Intelligence venture capital transaction
Next: 1/10/2025: MoneySuperMarket venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to report on tech company VC transactions. All VC database entries reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2025. Gaebler Ventures. All rights reserved.